|

Dual-target CAR-NK cell product Clinical Trials

2 actively recruiting trials

▲ +1 trial since June 2026

Pipeline

Phase 1/2: 2

Top Sponsors

  • Beijing Biotech2

Indications

  • Recurrent or Refractory Disease After Standard Therapies2
  • Primary Peritoneal Carcinoma2
  • Fallopian Tube Carcinoma2
  • Epithelial Ovarian Cancer2
  • Cancer2

Other2 trials

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Phase 1/2
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.